Welcome to Paid Research Studies




  • Condition:   Gynecologic Disease
    Interventions:   Device: 3D saline infusion sonohysterography;   Device: Office Hysteroscopy
    Sponsor:   Woman's Health University Hospital, Egypt
    Recruiting - verified May 2017

  • Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
    Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting - verified June 2017

  • Condition:   GYN Disorders
    Interventions:   Device: Group 1: Nella VuSleeve;   Device: Group 2: Nella NuSpec;   Device: Group 3: NellaSpec;   Device: Group 4: Nella Insert
    Sponsor:   Ceek Enterprises
    Recruiting - verified April 2017

  • Conditions:   Endometrial Cancer;   Papillary Serous;   Clear Cell Endometrial Cancer
    Intervention:   Radiation: Vaginal Cuff Brachytherapy
    Sponsor:   University of Oklahoma
    Not yet recruiting - verified June 2017

  • Conditions:   Urinary Tract Infections;   Urinary Retention;   Satisfaction
    Intervention:   Other: Fast Track foley removal
    Sponsor:   The Christ Hospital
    Recruiting - verified April 2017

  • Condition:   Gynecologic Neoplasms
    Interventions:   Drug: Atezolizumab;   Drug: Rucaparib
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified July 2017

  • Condition:   Malignant Neoplasms of Female Genital Organs
    Interventions:   Behavioral: Questionnaires;   Device: Conventional Insufflation System (CIS);   Device: ConMed AirSeal Insufflation System (AIS) at Low Pressure;   Device: ConMed AirSeal Insufflation System (AIS) at Higher Pressure
    Sponsors:   M.D. Anderson Cancer Center;   ConMed Corporation
    Not yet recruiting - verified April 2017

  • Condition:   Malignant Neoplasm of Cervix, Endometrium and Ovary
    Intervention:   Procedure: Approach for cancer resection
    Sponsor:   Mansoura University
    Recruiting - verified August 2016

  • Conditions:   Head and Neck Cancer;   Prostate Cancer;   Breast Cancer;   Lung Cancer;   Gynecologic Cancer;   Gastrointestinal Cancer
    Interventions:   Other: Survey;   Other: Saliva sample;   Other: Smoking Status questions;   Other: Health Services
    Sponsor:   Medical University of South Carolina
    Recruiting - verified November 2016

  • Condition:   Gynecologic Disease
    Interventions:   Device: Mediclore;   Device: Adept
    Sponsor:   Yong Sang Song
    Recruiting - verified January 2017

  • Condition:   Curcumin Use for Gynecological Conditions
    Intervention:   Dietary Supplement: Curcumin supplementation
    Sponsor:   Meir Medical Center
    Not yet recruiting - verified October 2016

  • Conditions:   Gynecologic Cancer;   Pathological Constriction
    Interventions:   Behavioral: Pelvic Physiotherapy;   Behavioral: Standard care (SC)
    Sponsors:   Federal University of Health Science of Porto Alegre;   Irmandade Santa Casa de Misericórdia de Porto Alegre
    Not yet recruiting - verified March 2017

  • Condition:   Gynecologic Disease
    Intervention:   Device: Mediclore® (adhesion barrier)
    Sponsor:   CGBio Inc.
    Recruiting - verified November 2016

  • Conditions:   Urinary Incontinence;   Urinary Stress Incontinence;   Pregnancy Complications
    Intervention:  
    Sponsor:   Oslo University Hospital
    Recruiting - verified January 2017

  • Conditions:   Cervical Cancer;   Uterine Cancer;   Vaginal Cancer;   Vulvar Cancer;   Bladder Cancer
    Intervention:   Device: Image-Guided Brachytherapy
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified December 2016

  • Conditions:   Gynecologic Condition;   Scheduled for a Total Laparoscopic or Robotic-assisted Hysterectomy
    Intervention:   Procedure: YUMI manipulator
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting - verified October 2016

  • Conditions:   Gynecologic Neoplasms;   Cognition Disorders
    Intervention:   Behavioral: Emerging from the Haze class
    Sponsor:   Cedars-Sinai Medical Center
    Not yet recruiting - verified September 2016

  • Conditions:   Gynecologic Neoplasms;   Venous Thromboembolism;   Low Molecular Weight Heparin;   Argatroban
    Interventions:   Drug: s-LMWH;   Drug: LMWH;   Drug: Argatroban
    Sponsor:   Huazhong University of Science and Technology
    Recruiting - verified October 2016

  • Conditions:   Cervical Cancer;   Uterine Cancer
    Interventions:   Drug: Cisplatin;   Drug: Cisplatin;   Procedure: Peritoneal mesometrial resection;   Procedure: Radical hysterectomy;   Radiation: Concurrent chemoradiation therapy (CCRT);   Procedure: Laterally extended endopelvic resection, Total mesometrial resection;   Procedure: Total mesometrial resection;   Drug: 5-fluorouracil, Cisplatin;   Drug: 5-fluorouracil, Cisplatin;   Drug: Doxorubicin, Cisplatin;   Procedure: Staging operation;   Radiation: Radiotherapy or Concurrent chemoradiation therapy (CCRT);   Radiation: Concurrent chemoradiation therapy (CCRT)
    Sponsor:   Seoul National University Hospital
    Recruiting - verified December 2016

  • Condition:   Postoperative Pain
    Interventions:   Device: Acupuncture;   Device: Sham acupuncture
    Sponsor:   The University of Hong Kong
    Not yet recruiting - verified July 2016

  • Conditions:   Breast Cancer;   Cervix Cancer;   Ovarian Cancer;   Endometrial Cancer
    Intervention:   Drug: carbplatin, cyclophophamide, atezolizumab
    Sponsors:   The Netherlands Cancer Institute;   Roche Pharma AG
    Recruiting - verified April 2017

  • Conditions:   Pain;   Pneumoperitoneum;   Inflammation;   Quality of Life
    Intervention:   Procedure: Pneumoinsufflator mode and setting
    Sponsors:   The Cleveland Clinic;   ConMed Corporation
    Recruiting - verified July 2017

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Uterine Endometrial Cancer
    Intervention:  
    Sponsors:   Duke University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified April 2017

  • Conditions:   Male Urogenital Diseases;   Female Urogenital Diseases
    Interventions:   Device: Aisys with Et control;   Device: Aisys conventional;   Device: Flow-i with ACG;   Device: Flow-i conventional
    Sponsors:   St. Olavs Hospital;   Norwegian University of Science and Technology
    Recruiting - verified December 2016

  • Conditions:   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Gynecologic Neoplasms;   Fallopian Tube Neoplasms;   Vulvar Neoplasms;   Vaginal Neoplasms;   Peritoneal Neoplasms
    Intervention:   Behavioral: Specialized Symptom Management and Supportive Care
    Sponsor:   University of Michigan
    Recruiting - verified June 2017

  • Conditions:   Gynecologic Neoplasms;   Epithelial Ovarian Cancer;   Uterine Endometrial Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Intervention:   Drug: Pembrolizumab
    Sponsors:   AA Secord;   Merck Sharp & Dohme Corp.
    Recruiting - verified March 2017

  • Conditions:   Small Cell Lung Cancer;   Ovarian Cancer
    Interventions:   Drug: LCL161;   Drug: Topotecan
    Sponsors:   SCRI Development Innovations, LLC;   Novartis Pharmaceuticals
    Recruiting - verified April 2017

  • Conditions:   Genital Neoplasms, Female;   Insomnia;   Pain;   Adaptation, Psychological
    Interventions:   Behavioral: Cognitive Behavioral Therapy;   Behavioral: Psychoeducation
    Sponsors:   University of Florida;   University of Miami;   National Cancer Institute (NCI)
    Recruiting - verified July 2017

  • Conditions:   Anxiety;   Cancer Survivor;   Cognitive Impairment;   Depression;   Distress;   Fatigue;   Malignant Female Reproductive System Neoplasm;   Pain;   Sexual Dysfunction
    Intervention:   Behavioral: Mindfulness-Based Stress Reduction
    Sponsor:   University of Wisconsin, Madison
    Recruiting - verified September 2016

  • Conditions:   Breast Cancer;   Ovarian Cancer;   Uterine Cancer;   Cervical Cancer
    Interventions:   Behavioral: Hypnotic Relaxation Therapy;   Behavioral: Progressive Muscle Relaxation
    Sponsors:   University of Michigan;   Breast Cancer Research Foundation
    Recruiting - verified April 2017

  • Conditions:   Breast Cancer;   Breast Tumor;   Gynecologic Cancer
    Intervention:   Genetic: Genetic profiling
    Sponsor:   Avera McKennan Hospital & University Health Center
    Recruiting - verified March 2017

  • Conditions:   Neoplasms;   Ovarian Neoplasms;   Uterine Neoplasms;   Vulva
    Intervention:   Behavioral: BBI intervention
    Sponsor:   Rachel Miller
    Recruiting - verified November 2016

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Cervical Cancer;   Peritoneal Cancer;   Head and Neck Cancer
    Intervention:   Drug: COTI2
    Sponsors:   Critical Outcome Technologies Inc.;   M.D. Anderson Cancer Center;   Northwestern Memorial Hospital
    Recruiting - verified February 2017

  • Conditions:   Cervical Carcinoma;   Ovarian Carcinoma;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
    Interventions:   Procedure: Supportive Care;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2017

  • Conditions:   Gynecologic Cancer;   Venous Thromboembolism
    Interventions:   Drug: Oral apixaban;   Drug: Subcutaneous enoxaparin
    Sponsors:   University of Colorado, Denver;   Bristol-Myers Squibb
    Recruiting - verified May 2017

  • Conditions:   Acupuncture;   Taste Disorders;   Dysgeusia;   Chemotherapy;   Cancer
    Interventions:   Other: Hypoglossal acupuncture;   Other: Sham acupuncture;   Behavioral: Dietary recommendations
    Sponsor:   Universität Duisburg-Essen
    Recruiting - verified February 2017

  • Conditions:   Ovarian Cancer;   Cervical Cancer;   Uterine Cancer;   Anemia
    Interventions:   Other: Oral Ferrous Fumarate;   Other: Placebo
    Sponsor:   Sunnybrook Health Sciences Centre
    Recruiting - verified April 2017

  • Conditions:   Healthy Subject;   Localized Transitional Cell Cancer of the Renal Pelvis and Ureter;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Psychosocial Effects of Cancer and Its Treatment;   Recurrent Bladder Cancer;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Gastric Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Uterine Sarcoma;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage II Bladder Cancer;   Stage II Renal Cell Cancer;   Stage II Urethral Cancer;   Stage IIA Cervical Cancer;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Cervical Cancer;   Stage IIB Colon Cancer;   Stage IIB Gastric Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Colon Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Bladder Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage III Urethral Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Cervical Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Bladder Cancer;   Stage IV Gastric Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IV Urethral Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Cervical Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Stage IVB Uterine Sarcoma;   Ureter Cancer;   Stage IIA Lung Carcinoma;   Stage IIB Lung Carcinoma;   Stage IIIA Lung Carcinoma;   Stage IIIB Lung Carcinoma
    Interventions:   Other: educational intervention;   Behavioral: telephone-based intervention;   Procedure: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI);   American Cancer Society (ACS) National Office
    Recruiting - verified February 2017

  • Conditions:   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Stage I Uterine Sarcoma;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage IC Primary Peritoneal Cavity Cancer;   Stage II Endometrial Carcinoma;   Stage II Gestational Trophoblastic Tumor;   Stage II Uterine Sarcoma;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage III Gestational Trophoblastic Tumor;   Stage III Uterine Sarcoma;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Breast Cancer
    Interventions:   Other: behavioral, psychological or informational intervention;   Other: behavioral, psychological or informational intervention
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2017

  • Conditions:   Breast Carcinoma;   Cancer Survivor;   Cognitive Side Effects of Cancer Therapy;   Malignant Female Reproductive System Neoplasm
    Interventions:   Other: Cognitive Intervention;   Other: Educational Intervention;   Procedure: Functional Magnetic Resonance Imaging;   Other: Memory Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Adenovirus;   Adrenal Insufficiency;   Airway Swelling;   Anesthesia;   Anxiety;   Anxiolysis;   Autism;   Autistic Disorder;   Bacterial Meningitis;   Bacterial Septicemia;   Benzodiazepine;   Bipolar Disorder;   Bone and Joint Infections;   Brain Swelling;   Central Nervous System Infections;   Convulsions;   Cytomegalovirus Retinitis;   Early-onset Schizophrenia Spectrum Disorders;   Edema;   Epilepsy;   General Anesthesia;   Gynecologic Infections;   Headaches;   Herpes Simplex Virus;   Hypertension;   Infantile Hemangioma;   Infection;   Inflammation;   Inflammatory Conditions;   Influenza;   Intra-abdominal Infections;   Lower Respiratory Tract Infections;   Migraines;   Pain;   Pneumonia;   Prophylaxis;   Schizophrenia;   Sedation;   Seizures;   Skeletal Muscle Spasms;   Skin and Skin-structure Infections;   Stable Angina;   Thromboprophylaxis;   Thrombosis;   Treatment-resistant Schizophrenia;   Urinary Tract Infection;   Withdrawal
    Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
    Recruiting - verified March 2017

  • Conditions:   Cervical Cancer;   Endometrial Cancer;   Vaginal Cancer;   Vulvar Cancer;   Gynecologic Cancer
    Intervention:   Behavioral: Questionnaires
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified November 2016

  • Conditions:   Gynecologic Disease;   Gynecologic Cancer
    Intervention:  
    Sponsors:   James Graham Brown Cancer Center;   University of Louisville
    Recruiting - verified November 2016